FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17

Article Link: FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17

PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use in the treatment of…

Source: FDA New Drug Approvals